Traitements de fond de la sclérose en plaques : enseignements des études randomisées comparatives directes

Brex, 2002, A longitudinal study of abnormalities on MRI and disability from multiple sclerosis, N Engl J Med, 346, 158, 10.1056/NEJMoa011341 Cadavid, 2007, Betaseron versus copaxone in multiple sclerosis with triple-dose gadolinium and 3 Tesla MRI Endpoints (BECOME): announcement of secondary clinical outcomes, Mult Scler, 13, P207 Clanet, 2002, A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS, Neurology, 59, 1507, 10.1212/01.WNL.0000032256.35561.D6 Comi, 2008, Results from a phase III, one-year, randomized, double-blind, parallel-group, dose comparison study with glatiramer acetate in relapsing-remitting multiple sclerosis, Mult Scler, 14, S299 Comi, 2001, Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, Lancet, 357, 1576, 10.1016/S0140-6736(00)04725-5 Comi, 2001, Ann Neurol, 49, 290, 10.1002/ana.64 Comi G, PreCISe STudy Group. Early glatiramer acetate treatment in delaying conversion to clinically definite multiple sclerosis (CDMS) in subjects presenting with a clinically isolated syndrome. Neurology 2008;70: Late Breaking Science (Suppl):9. Durelli, 2002, Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN), Lancet, 359, 1453, 10.1016/S0140-6736(02)08430-1 Edan, 1997, Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria, J Neurol Neurosurg Psychiatry, 62, 112, 10.1136/jnnp.62.2.112 Edan, 2007, The French-Italian Mitoxantrone-Interferon-beta Trial: a 3-year randomised study, Mult Scler, 13 Engelhardt, 2008, Natalizumab: targeting alpha4-integrins in multiple sclerosis, Neurodegener Dis, 5, 16, 10.1159/000109933 Fisniku, 2008, Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis, Brain, 131, 808, 10.1093/brain/awm329 Fox, 2004, Mechanism of action of mitoxantrone, Neurology, 63, S15, 10.1212/WNL.63.12_suppl_6.S15 Freedman, 2005, Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study, Mult Scler, 11, 41, 10.1191/1352458505ms1126oa Jacobs, 2000, Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group, N Engl J Med, 343, 898, 10.1056/NEJM200009283431301 Jacobs, 1996, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG), Ann Neurol, 39, 285, 10.1002/ana.410390304 Johnson, 1995, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, 45, 1268, 10.1212/WNL.45.7.1268 Kappos, 2006, Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, 67, 1242, 10.1212/01.wnl.0000237641.33768.8d Khan, 2001, A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy, Mult Scler, 7, 349 Koch-Henriksen, 2006, A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis, Neurology, 66, 1056, 10.1212/01.wnl.0000204018.52311.ec Le Page, 2008, Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients, J Neurol Neurosurg Psychiatry, 79, 52, 10.1136/jnnp.2007.124958 Markowitz, 2007, Interferon-beta: mechanism of action and dosing issues, Neurology, 68, S8, 10.1212/01.wnl.0000277703.74115.d2 Mikol, 2008, Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial, Lancet Neurol, 7, 903, 10.1016/S1474-4422(08)70200-X O’Connor P, Arnason B, Comi G, Filippi M, Cook S, Goodin D, et al. Interferon beta-1b 500mcg, interferon beta-1b 250mcg and glatiramer acetate: primary outcomes of the Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose) study. Neurology 2008; 70:(Late Breaking Science Suppl.):4. Panitch, 2002, Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial, Neurology, 59, 1496, 10.1212/01.WNL.0000034080.43681.DA PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–504. Ramtahal, 2006, Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis, J Neurol, 253, 1160, 10.1007/s00415-006-0178-z Rudick, 2006, Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, N Engl J Med, 354, 911, 10.1056/NEJMoa044396 The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655–61. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277–85. The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999;53:679–86. Tintoré, 2008, Rationale for early intervention with immunomodulatory treatments, J Neurol, 255, 37, 10.1007/s00415-008-1006-4 US Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Baltimore, MD: Williams and Wilkins; 1996. Weber, 2007, Mechanism of action of glatiramer acetate in treatment of multiple sclerosis, Neurotherapeutics, 4, 647, 10.1016/j.nurt.2007.08.002 Wolansky, 2007, Betaseron vs Copaxone in MS with triple-dose gadolinium and 3-T MRI Endpoints (BECOME): announcement of final primary study outcome, Mult Scler, 13, P207